Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-599cfd5f84-z6fpd Total loading time: 0 Render date: 2025-01-07T07:37:14.471Z Has data issue: false hasContentIssue false

Chapter 16 - Plasma Cell Neoplasia

Published online by Cambridge University Press:  12 November 2020

Jon van der Walt ,
Attilio Orazi  and
Daniel A. Arber
By
Falko Fend
Jon van der Walt
Affiliation:
St Thomas’ Hospital, London
Attilio Orazi
Affiliation:
Texas Tech University
Daniel A. Arber
Affiliation:
University of Chicago
Get access

Summary

Plasma cell neoplasms are derived from mature, IG heavy chain class-switched terminally differentiated B-cells, which usually secrete a monoclonal immunoglobulin or M-protein and consist of a homogeneous population of neoplastic plasma cells [1]. Plasma cell myeloma (PCM) is a common malignancy, manifesting itself by bone marrow (BM) infiltration and bone destruction, and therefore representing an entity frequently encountered in BM biopsies(BMB). Its precursor lesion, non-IgM monoclonal gammopathy of unknown significance (MGUS) is a frequent finding in elderly individuals and shows a low, but definite risk for progression to PCM. In this chapter, we will discuss the diagnosis and differential diagnosis of PCM, MGUS and clonal plasma cell disorders with associated paraneoplastic syndromes, including POEMS syndrome and TEMPI syndrome. Amyloidosis is discussed in Chapter 3, and other mature B-cell neoplasms with a clonal plasma cell component in Chapter 15.

Keywords

Plasma cellplasmacytosismonoclonal gammopathymyelomaplamablasticleukaemiaamyloidPOEMS
Type
Chapter
Information
Diagnostic Bone Marrow Haematopathology , pp. 283 - 297
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

McKenna, RW, Kyle, RD, Kuehl, WM, et al. Plasma cell neoplasms. In Swerdlow, SH, Campo, E, Harris, NL, et al. (eds) WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon: IARC; 2017:241–53.Google Scholar
International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–57.Google Scholar
Berenson, JR, Anderson, KC, Audell, RA, et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010;150(1):28–38.CrossRefGoogle ScholarPubMed
Kyle, RA, Durie, BG, Rajkumar, SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121–7.Google Scholar
Weiss, BM, Kuehl, WM. Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Rev Hematol. 2010;3(2):165–74.CrossRefGoogle ScholarPubMed
Kyle, RA, Therneau, TM, Rajkumar, SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362–9.CrossRefGoogle ScholarPubMed
Rajkumar, SV, Dispenzieri, A, Kyle, RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc. 2006;81(5):693–703.CrossRefGoogle ScholarPubMed
Xu, L, Hunter, ZR, Yang, G, et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051–8.Google Scholar
Perez-Persona, E, Mateo, G, Garcia-Sanz, R, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol. 2010;148(1):110–14.Google Scholar
Costes, V, Magen, V, Legouffe, E, et al. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol. 1999;30(12):1405–11.CrossRefGoogle ScholarPubMed
Ely, SA, Knowles, DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol. 2002;160(4):1293–9.Google Scholar
Kaufmann, H, Ackermann, J, Baldia, C, et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia. 2004;18(11):1879–82.Google Scholar
Fonseca, R, Barlogie, B, Bataille, R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64(4):1546–58.Google Scholar
Hallek, M, Bergsagel, L, Anderson, KC. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood. 1998;913–21.CrossRefGoogle Scholar
Robiou du Pont, S, Cleynen, A, Fontan, C, et al. Genomics of multiple myeloma. J Clin Oncol. 2017;35(9):963–7.CrossRefGoogle ScholarPubMed
Kyle, RA, Remstein, ED, Therneau, TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582–90.Google Scholar
Rajkumar, SV, Dimopoulos, MA, Palumbo, A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.CrossRefGoogle Scholar
Rajkumar, SV, Kyle, RA, Buadi, FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc. 2010;85(10):945–8.CrossRefGoogle ScholarPubMed
Kyle, RA, Therneau, TM, Rajkumar, SV, et al. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer. 2004;101(11):2667–74.Google Scholar
Blade, J, Kyle, RA, Greipp, PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol. 1996;93(2):345–51.CrossRefGoogle Scholar
Zamagni, E, Cavo, M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol. 2012;159(5):499–513.Google Scholar
Kyle, RA, Gertz, MA, Witzig, TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33.Google Scholar
Coriu, D, Weaver, K, Schell, M, et al. A molecular basis for nonsecretory myeloma. Blood. 2004;104(3):829–31.Google Scholar
Kremer, M, Ott, G, Nathrath, M, et al. Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. J Pathol. 2005;20,592–101.Google Scholar
Durie, BG, Salmon, SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–54.Google Scholar
Greipp, PR, San Miguel, J, Durie, BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–20.Google Scholar
Palumbo, A, Avet-Loiseau, H, Oliva, S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–9.Google Scholar
Robillard, N, Avet-Loiseau, H, Garand, R, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood. 2003;102(3):1070–1.Google Scholar
Bartl, R, Frisch, B, Fateh-Moghadam, A, et al. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987;87(3):342–55.Google Scholar
Greipp, PR, Leong, T, Bennett, JM, et al. Plasmablastic morphology: an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91(7):2501–7.CrossRefGoogle ScholarPubMed
Jones, D, Bhatia, VK, Krausz, T, Pinkus, GS. Crystal-storing histiocytosis: a disorder occurring in plasmacytic tumors expressing immunoglobulin kappa light chain. Hum Pathol. 1999;30(12):1441–8.CrossRefGoogle ScholarPubMed
Lebeau, A, Zeindl-Eberhart, E, Muller, EC, et al. Generalized crystal-storing histiocytosis associated with monoclonal gammopathy: molecular analysis of a disorder with rapid clinical course and review of the literature. Blood. 2002;100(5):1817–27.CrossRefGoogle ScholarPubMed
Grogan, TM. Plasma cell myeloma marrow diagnosis including morphologic and phenotypic features. Semin Diagn Pathol. 2003;20(3):211–25.Google Scholar
Petruzziello, F, Zeppa, P, Catalano, L, et al. Amyloid in bone marrow smears of patients affected by multiple myeloma. Ann Hematol. 2010;89(5):469–74.Google Scholar
Joshi, R, Horncastle, D, Elderfield, K, et al. Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients. J Clin Pathol. 2008;61(2):213–6.Google ScholarPubMed
Kremer, M, Quintanilla-Martinez, L, Nahrig, J, von Schilling, C, Fend, F. Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosis. Virchows Arch. 2005;447(6):920–37.Google Scholar
Gualco, G, Weiss, LM, Bacchi, CE. MUM1/IRF4: a review. Appl Immunohistochem Mol Morphol. 2010;18(4):301–10.Google Scholar
Ng, AP, Wei, A, Bhurani, D, et al. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Haematologica. 2006;91(7):972–5.Google Scholar
Pileri, S, Poggi, S, Baglioni, P, et al. Histology and immunohistology of bone marrow biopsy in multiple myeloma. Eur J Haematol Suppl. 1989;5152–9.Google Scholar
San Miguel, JF, Vidriales, MB, Ocio, E, et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):187–95.Google Scholar
Lin, P, Mahdavy, M, Zhan, F, et al. Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol. 2004;17(10):1217–22.Google Scholar
Lorsbach, RB, Hsi, ED, Dogan, A, Fend, F. Plasma cell myeloma and related neoplasms. Am J Clin Pathol. 2011;136(2):168–82.CrossRefGoogle ScholarPubMed
Lugli, A, Went, P, Khanlari, B, Nikolova, Z, Dirnhofer, S. Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment. Virchows Arch. 2004;444(3):264–8.CrossRefGoogle ScholarPubMed
Specht, K, Haralambieva, E, Bink, K, et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood. 2004;104(4):1120–6.Google Scholar
Pruneri, G, Fabris, S, Baldini, L, et al. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol. 2000;156(5):1505–13.Google Scholar
Chng, WJ, Huang, GF, Chung, TH, et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 2011;25(6):1026–35.Google Scholar
Xiao, R, Cerny, J, Devitt, K, et al. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS). Am J Surg Pathol. 2014;38(6):776–83.Google Scholar
Baldus, SE, Palmen, C, Thiele, J. MUC1 (EMA) expressing plasma cells in bone marrow infiltrated by plasma cell myeloma. Histol Histopathol. 2007;22(8):889–93.Google ScholarPubMed
Majumdar, G, Grace, RJ, Singh, AK, Slater, NG. The value of the bone marrow plasma cell cytoplasmic light chain ratio in differentiating between multiple myeloma and monoclonal gammopathy of undetermined significance. Leuk Lymphoma. 1992;8(6):491–3.CrossRefGoogle ScholarPubMed
Beck, RC, Tubbs, RR, Hussein, M, Pettay, J, Hsi, ED. Automated colorimetric in situ hybridization (CISH) detection of immunoglobulin (Ig) light chain mRNA expression in plasma cell (PC) dyscrasias and non-Hodgkin lymphoma. Diagn Mol Pathol. 2003;12(1):14–20.CrossRefGoogle ScholarPubMed
Feyler, S, O’Connor, SJ, Rawstron, AC, et al. IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14). Br J Haematol. 2008;140(5):547–51.CrossRefGoogle ScholarPubMed
Gu, HJ, Cho, SY, Lee, J, Sung, JY, Park, TS. Biclonal plasma cell myeloma with the simultaneous appearance of both secretory lambda and nonsecretory kappa monoclonal light chains. Clin Chem Lab Med. 2017;55(1):e21–e24.Google Scholar
Paiva, B, Almeida, J, Perez-Andres, M, et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom. 2010;78(4):239–52.Google Scholar
Kumar, S, Paiva, B, Anderson, KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e46.Google Scholar
Bakkus, MH, Heirman, C, Van Riet, I, Van Camp, B, Thielemans, K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood. 1992;80(9):2326–35.Google Scholar
Fonseca, R, Bergsagel, PL, Drach, J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210–21.Google Scholar
Avet-Loiseau, H, Facon, T, Grosbois, B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99(6):2185–91.CrossRefGoogle Scholar
Bergsagel, PL, Chesi, M, Nardini, E, et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA. 1996;93(24):13,931–6.Google Scholar
Fonseca, R, Blood, E, Rue, M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569–75.Google Scholar
Morgan, GJ, Walker, BA, Davies, FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335–48.Google Scholar
Avet-Loiseau, H, Garand, R, Lode, L, Harousseau, JL, Bataille, R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101(4):1570–1.Google Scholar
Fernandez de Larrea, C, Kyle, RA, Durie, BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27(4):780–91.Google Scholar
Garcia-Sanz, R, Orfao, A, Gonzalez, M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93(3):1032–7.Google Scholar
Avet-Loiseau, H, Daviet, A, Brigaudeau, C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood. 2001;97(3):822–5.Google Scholar
Pellat-Deceunynck, C, Barille, S, Jego, G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12(12):1977–82.Google Scholar
Ioannou, MG, Stathakis, E, Lazaris, AC, et al. Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses. Pathol Oncol Res. 2009;15(1):25–9.Google Scholar
Martin, P, Santon, A, Bellas, C. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis. Histopathology. 2004;44(4):375–80.CrossRefGoogle ScholarPubMed
Rawstron, AC, Orfao, A, Beksac, M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431–8.Google Scholar
Grogg, KL, Morice, WG, Macon, WR. Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol. 2007;137(5):416–22.Google Scholar
Vasef, MA, Medeiros, LJ, Yospur, LS, et al. Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol. 1997;10(9):927–32.Google Scholar
Pantic, M, Schroettner, P, Pfeifer, D, et al. Biclonal origin prevails in concomitant chronic lymphocytic leukemia and multiple myeloma. Leukemia. 2010;24(4):885–90.CrossRefGoogle ScholarPubMed
Seegmiller, AC, Xu, Y, McKenna, RW, Karandikar, NJ. Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. Am J Clin Pathol. 2007;127(2):176–81.Google Scholar
Vega, F, Chang, CC, Medeiros, LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005;18(6):806–15.Google Scholar
Bardwick, PA, Zvaifler, NJ, Gill, GN, et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine. 1980;59(4):311–22.Google Scholar
Dispenzieri, A. How I treat POEMS syndrome. Blood. 2012;119(24):5650–8.Google Scholar
Dispenzieri, A. POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(2):214–23.Google Scholar
Dao, LN, Hanson, CA, Dispenzieri, A, et al. Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood. 2011;117(24):6438–44.Google Scholar
Bazari, H, Attar, EC, Dahl, DM, Uppot, RN, Colvin, RB. Case records of the Massachusetts General Hospital. Case 23-2010. A 49-year-old man with erythrocytosis, perinephric fluid collections, and renal failure. N Engl J Med. 2010;363(5):463–75.CrossRefGoogle ScholarPubMed
Sykes, DB, Schroyens, W, O’Connell, C. The TEMPI syndrome: a novel multisystem disease. N Engl J Med. 2011;365(5):475–7.Google Scholar
Rosado, FG, Oliveira, JL, Sohani, AR, et al. Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist. Mod Pathol. 2015;28(3):367–72.Google Scholar
Bain, BJ, Ahmad, S. Chronic neutrophilic leukaemia and plasma cell-related neutrophilic leukaemoid reactions. Br J Haematol. 2015;171(3):400–10.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×